AngioDynamics, Inc. (ANGO): Price and Financial Metrics


AngioDynamics, Inc. (ANGO): $12.06

-0.14 (-1.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ANGO POWR Grades

  • ANGO scores best on the Growth dimension, with a Growth rank ahead of 84.04% of US stocks.
  • The strongest trend for ANGO is in Momentum, which has been heading down over the past 178 days.
  • ANGO ranks lowest in Momentum; there it ranks in the 10th percentile.

ANGO Stock Summary

  • ANGO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 125.35 -- higher than 82.61% of US-listed equities with positive expected earnings growth.
  • ANGO's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 18.12% of US stocks.
  • With a year-over-year growth in debt of 99.19%, ANGIODYNAMICS INC's debt growth rate surpasses 87.94% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ANGIODYNAMICS INC are ISPC, MYGN, HBIO, JMIA, and LIQT.
  • ANGO's SEC filings can be seen here. And to visit ANGIODYNAMICS INC's official web site, go to www.angiodynamics.com.

ANGO Valuation Summary

  • ANGO's EV/EBIT ratio is -14.7; this is 268.97% lower than that of the median Healthcare stock.
  • ANGO's price/earnings ratio has moved down 85.8 over the prior 225 months.

Below are key valuation metrics over time for ANGO.

Stock Date P/S P/B P/E EV/EBIT
ANGO 2022-12-02 1.5 1.2 -14.6 -14.7
ANGO 2022-12-01 1.6 1.2 -15.3 -15.3
ANGO 2022-11-30 1.6 1.2 -15.5 -15.5
ANGO 2022-11-29 1.5 1.2 -15.0 -15.0
ANGO 2022-11-28 1.5 1.2 -15.0 -15.0
ANGO 2022-11-25 1.7 1.3 -16.4 -16.4

ANGO Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 76.5%.
  • The 4 year cash and equivalents growth rate now stands at -23.84%.
  • Its 4 year net income to common stockholders growth rate is now at 279.15%.
ANGO's revenue has moved down $23,500,000 over the prior 52 months.

The table below shows ANGO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 320.785 -23.035 -32.579
2022-06-30 316.219 -7.194 -26.547
2022-03-31 306.063 -3.555 -39.749
2021-12-31 303.275 11.107 -38.335
2021-09-30 297.765 20.614 -34.252
2021-06-30 291.01 24.093 -31.548

ANGO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ANGO has a Quality Grade of D, ranking ahead of 15.86% of graded US stocks.
  • ANGO's asset turnover comes in at 0.521 -- ranking 88th of 186 Medical Equipment stocks.
  • CLPT, EW, and IVC are the stocks whose asset turnover ratios are most correlated with ANGO.

The table below shows ANGO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-08-31 0.521 0.541 -0.324
2021-05-31 0.503 0.539 -0.282
2021-02-28 0.464 0.531 -1.297
2020-11-30 0.434 0.540 -1.344
2020-08-31 0.407 0.551 -1.516
2020-05-31 0.385 0.569 -1.758

ANGO Price Target

For more insight on analysts targets of ANGO, see our ANGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $30.00 Average Broker Recommendation 1.5 (Moderate Buy)

ANGO Stock Price Chart Interactive Chart >

Price chart for ANGO

ANGO Price/Volume Stats

Current price $12.06 52-week high $30.00
Prev. close $12.20 52-week low $11.93
Day low $11.93 Volume 693,840
Day high $12.25 Avg. volume 320,376
50-day MA $14.93 Dividend yield N/A
200-day MA $19.91 Market Cap 471.64M

AngioDynamics, Inc. (ANGO) Company Bio


AngioDynamics designs, manufactures, and sells various medical, surgical, and diagnostic devices for vascular access, surgery, peripheral vascular disease, and oncology in the United States and internationally. The company was founded in 1988 and is based in Latham, New York.


ANGO Latest News Stream


Event/Time News Detail
Loading, please wait...

ANGO Latest Social Stream


Loading social stream, please wait...

View Full ANGO Social Stream

Latest ANGO News From Around the Web

Below are the latest news stories about ANGIODYNAMICS INC that investors may wish to consider to help them evaluate ANGO as an investment opportunity.

A number of insiders bought AngioDynamics, Inc. (NASDAQ:ANGO) stock last year, which is great news for shareholders

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

Yahoo | November 25, 2022

AngioDynamics to Present at the Piper Sandler Healthcare Conference

LATHAM, N.Y., November 17, 2022--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Piper Sandler 34th Annual Healthcare Conference at 10:

Yahoo | November 17, 2022

Intuitive Surgical, Inc. (ISRG) Up 24.6% Since Last Earnings Report: Can It Continue?

Intuitive Surgical, Inc. (ISRG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | November 17, 2022

AngioDynamics Announces First Patient Enrolled in APEX-AV Study Assessing AlphaVac F1885 PE System in Treatment of Pulmonary Embolism

LATHAM, N.Y., October 31, 2022--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the enrollment of the first patient in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV), a clinical study aimed at evaluating the efficacy and safety of the Company’s AlphaVac M

Yahoo | October 31, 2022

Shareholders May Be A Bit More Conservative With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation For Now

In the past three years, shareholders of AngioDynamics, Inc. ( NASDAQ:ANGO ) have seen a loss on their investment...

Yahoo | October 29, 2022

Read More 'ANGO' Stories Here

ANGO Price Returns

1-mo -14.16%
3-mo -42.79%
6-mo -37.38%
1-year -52.96%
3-year -21.74%
5-year -29.10%
YTD -56.27%
2021 79.91%
2020 -4.25%
2019 -20.47%
2018 21.05%
2017 -1.42%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6874 seconds.